JP2004238349A - Antiobestic agent or/and prophylactic agent for arteriosclerosis containing terminalia catappa as active ingredient - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medicine or a food or beverage effective for prophylaxis/treatment of obesity/arteriosclerosis by utilizing a bioregulatory function which Terminalia catappa has in order to find an active ingredient from a food or a material based upon the food in prophylaxis/treatment of obesity/arteriosclerosis. <P>SOLUTION: It was confirmed by animal experience that a plant body of Terminalia catappa or its extract has bioactivity which has not been known hitherto. The medicine/food or beverage having antiobestic action or action for preventing/improving arteriosclerosis comprises the plant body of Terminalia catappa or an extract obtained by carrying out extraction treatment of the plant body of Terminalia catappa with water or an organic solvent alone or a mixture thereof as an active ingredient. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【００２５】
実施例１３（モモタマナの抗肥満作用）
４週齢の雄性ＩＣＲ系マウスを９匹ずつ２群に分け、それぞれに精製飼料（ＡＩＮー９３Ｇ）、及びモモタマナ葉粉末を１％添加した精製飼料を７週間自由摂取させた。飼育終了後動物の体長（ヒトの身長に相当）・体重測定及び全採血を行い、血漿を分離して中性脂肪値、総コレステロール値、血糖値を測定した。精巣周囲脂肪と肝臓を摘出した後秤量し、肝臓中の中性脂肪、総コレステロール濃度を測定した。
表２に示した通り、エサにモモタマナを添加したところ、体長には変化が見られなかったものの、精巣周囲脂肪の重量が著しく低下し、体重も低下傾向を示した。
【００２６】

さらに表３に示した通り、モモタマナを与えた群の中性脂肪値、総コレステロール値、血糖値は、いずれも精製飼料のみを与えた群より低値であった。
【００２７】

また表４に示した通り、モモタマナを与えた群の肝臓中の中性脂肪、コレステロール蓄積量は、精製飼料のみを与えた群より著しく低値であった。
【００２８】

【００２９】
【発明の効果】
本発明によれば、モモタマナを原料として、抗肥満作用及び動脈硬化予防・改善作用を有する物質を得ることができた。更にこれを、医薬品や飲食品の材料として容易に利用することができた。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an antiobesity or / and arteriosclerosis preventive substance obtained from Momotamana and its use.
[0002]
[Prior art]
2. Description of the Related Art In recent years, the tendency of obesity in the people has been gradually increasing due to high fat and high calorie diet. Upper body obesity, impaired glucose tolerance, high triglyceride fat, and high blood pressure are called "quartets of death", and when they overlap, the incidence of arteriosclerosis and heart disease accelerates at an accelerated rate, and is thought to be life-threatening. Since the development of such physiological abnormalities is greatly influenced by environmental factors such as dietary factors, as well as transmission factors, it is sometimes necessary to make significant changes in lifestyle to prevent or improve the condition, making it difficult to sustain May be forced to self-regulate. There is a demand for a simple obesity / arteriosclerosis prevention / improvement method that can be accepted by everyone.
[0003]
In recent years, various useful substances have been found in foods or natural products equivalent thereto, and functional foods utilizing their physiological functions are becoming a boom. Functional foods are expected to improve blood lipids, blood sugar levels, blood pressure and the like when semi-healthy people take them on a daily basis, and can provide a simple means for promoting health and preventing disease.
Momotamana has a scientific name of "Terminaria catappa " and another name of "Koba Teishi". It is a tree of the family Aridaceae native to the Ogasawara Islands from Okinawa to the coasts of Asia and Africa, and its seeds are edible with a flavor similar to almonds. However, there are few studies focusing on the physiological function of Momotamana, and it is hardly used as a raw material for functional foods or pharmaceuticals. However, the leaves and the like contain a large amount of polyphenols, and are expected to have an anti-obesity effect including a fat absorption inhibitory effect, and a preventive / therapeutic effect for lifestyle-related diseases such as arteriosclerosis and heart disease.
[0004]
[Problems to be solved by the invention]
In the future, in preventing and treating obesity and arteriosclerosis, which will threaten the health of the nation, it is necessary to find active ingredients from foods or food equivalents. An object of the present invention is to provide a drug or a food or drink that is effective in preventing and treating obesity and arteriosclerosis by utilizing the biological regulation function of Momotamana.
[0005]
[Means for Solving the Problems]
The present invention has been made in order to achieve the above object, and completed the present invention by confirming, through animal experiments, that a plant of Momotamana or an extract thereof has a physiological activity that has not been known so far. I came to.
[0006]
That is, the present invention has an anti-obesity effect or an anti-arteriosclerosis-preventing / ameliorating effect, comprising as an active ingredient an extract obtained by extracting a plant of Momota mana, or a plant, with water or an organic solvent alone, or a mixture thereof. Provide medicines and foods and beverages.
[0007]
BEST MODE FOR CARRYING OUT THE INVENTION
In the case of using the plant body of Momotamana as it is, leaves, fruits, seeds, stems or roots are raw or dried, and then ground or powdered to an appropriate size.
[0008]
In extracting the extract, water, alcohol, or another organic solvent is used. A mixture of these may be used. A preferred extraction solvent is water or a mixed solvent of water and alcohol. The extraction is performed by room temperature extraction, heat extraction, and pressure extraction. -Generally at room temperature to 125 ° C. After the extraction treatment from the plant body, the solid content and the liquid are separated by centrifugation or the like, and further, if necessary, subjected to treatment such as filtration, and then concentrated under reduced pressure. Further, it can be powdered by vacuum drying, freeze drying or the like. Upon powdering, an appropriate excipient may be added.
[0009]
The processed plant or the extracted extract can be used as an oral pharmaceutical, or can be mixed with food materials to produce a food or drink. It takes a solid or liquid form as a property, and a pharmaceutical takes an oral dosage form such as a tablet, capsule, granule, syrup and the like.
When a plant or an extract is administered to the human body as a pharmaceutical, the dose of the plant or extract should be 0.1 to 1000 mg (dry weight) / kg body weight per dose, preferably 0.3 to 300 mg (dry weight) / kg body weight. Administer orally once or several times a day.
[0010]
In the case of food or drink, the food material mixed therewith may be any of a solid (powder, flake, lump, etc.), a semi-solid (jelly, syrup, etc.) or a liquid. The content of the plant or extract per 1 g of food or drink is desirably 0.3 to 300 mg (dry weight).
Pharmaceuticals and foods and drinks containing the plant or extract of Momotamana of the present invention have an anti-obesity effect and an effect of preventing and improving arteriosclerosis, and thus are effective in preventing and treating adult diseases and lifestyle-related diseases.
[0011]
【Example】
Hereinafter, the present invention will be described more specifically with reference to Examples, but the present invention is not limited thereto.
[0012]
Example 1 (Preparation of Momotamana hot water extract)
100 g of Momotamana leaves were finely ground, suspended in 1 L of distilled water, and boiled at 100 ° C. for 2 hours. After cooling the suspension, the suspension was centrifuged at 5000 G for 15 minutes, and the supernatant was collected and freeze-dried to obtain 24.8 g of extract powder. The polyphenol content in the peach tamana extract measured by the Folin-Ciocarte method was 44% in terms of (-) catechin.
[0013]
Example 2 (tablets, capsules)
Momotamana leaf powder 10.0g
Lactose 75.0g
Magnesium stearate 15.0g
100.0g in total
The above parts by weight were uniformly mixed to obtain tablets and capsules according to a conventional method.
[0014]
Example 3 (tablets, capsules)
10.0 g of the extract powder prepared in Example 1
Lactose 75.0g
Magnesium stearate 15.0g
100.0g in total
The above parts by weight were uniformly mixed to obtain tablets and capsules according to a conventional method.
[0015]
Example 4 (powder, granule)
Momotamana leaf powder 20.0g
Starch 30.0g
Lactose 50.0g
100.0g in total
The above parts by weight were uniformly mixed to give powders and granules according to a conventional method.
[0016]
Example 5 (powder, granule)
20.0 g of extract powder prepared in Example 1
Starch 30.0g
Lactose 50.0g
100.0g in total
The above parts by weight were uniformly mixed to give powders and granules according to a conventional method.
[0017]
Example 6 (candy)
Sucrose 20.0g
70.0g syrup (75% solids)
9.5 g of water
0.45 g coloring
Spice 0.045g
Momotamana leaf powder 0.005g
Total 100.0g
A candy was prepared according to a conventional method using the above components in each part by weight.
[0018]
Example 7 (candy)
Sucrose 20.0g
70.0g syrup (75% solids)
9.5 g of water
0.45 g coloring
Spice 0.045g
0.005 g of extract powder prepared in Example 1
Total 100.0g
A candy was prepared according to a conventional method using the above components in each part by weight.
[0019]
Example 8 (juice)
Concentrated orange juice 15.0g
Fructose 5.0g
Citric acid 0.2g
Spice 0.1g
0.15 g of pigment
Sodium ascorbate 0.048g
0.002 g of extract powder prepared in Example 1
79.5 g of water
Total 100.0g
A juice was prepared using the above-mentioned respective parts by weight and in accordance with a conventional method.
[0020]
Example 9 (cookie)
Soft flour 32.0g
16.0 g of whole egg
16.0 g of butter
Sugar 25.0g
10.8g of water
Baking powder 0.198g
Momotamana leaf powder 0.002g
Total 100.0g
A cookie was prepared according to a conventional method using the above components in each part by weight.
[0021]
Example 10 (cookie)
Soft flour 32.0g
16.0 g of whole egg
16.0 g of butter
Sugar 25.0g
10.8g of water
Baking powder 0.198g
0.002 g of extract powder prepared in Example 1
Total 100.0g
A cookie was prepared according to a conventional method using the above components in each part by weight.
[0022]
Example 11 (lipase inhibitory action of Momotamana)
1 mg / mL porcine pancreatic lipase, water or a 1 mg / mL aqueous solution of momotamana extract, and 0.1 mM methylumbelliferone oleate were mixed at a volume ratio of 1: 1: 1: 2 and reacted at room temperature for 60 minutes. After adding 5 volumes of 0.1N hydrochloric acid, 5 volumes of 0.1M trisodium citrate are further added, and the amount of fluorescence at an excitation of 320 nm and an absorption of 450 nm is measured, thereby releasing from methylumbelliferone oleate by lipase activity. The amount of 4-methylumbelliferone thus obtained was calculated. The addition of the aqueous solution of momotamana extract reduced the release amount of 4-methylumbelliferone by 36%, confirming that momotamana had a lipase inhibitory activity.
[0023]
Example 12 (Fat absorption inhibition effect of momotamana)
Orbital blood was collected from 6-week-old male ddY mice (9 mice per group), and 10 mL / kg of salad oil was orally administered, followed immediately by 10 mL / kg of water or 0.25 g / mL aqueous solution of momotamana extract powder. . After 180 minutes, orbital blood was collected again, the plasma was separated, and the neutral fat concentration was measured. The administration of Momotamana significantly suppressed the plasma triglyceride level 180 minutes after the salad oil load (Table 1).
[0024]

[0025]
Example 13 (Anti-obesity action of Momotamana)
Four-week-old male ICR mice were divided into two groups of nine each, and each group was allowed to freely ingest a purified feed (AIN-93G) and a purified feed to which 1% of momotamana leaf powder was added, for 7 weeks. After breeding, the animals were measured for body length (corresponding to human height) and body weight, and whole blood was collected. Plasma was separated and neutral fat, total cholesterol, and blood glucose were measured. The peritesticular fat and the liver were excised and weighed to measure the levels of neutral fat and total cholesterol in the liver.
As shown in Table 2, when momotamana was added to the food, there was no change in body length, but the weight of the peri-testicular fat was significantly reduced, and the body weight also tended to decrease.
[0026]

Furthermore, as shown in Table 3, the triglyceride, total cholesterol, and blood glucose levels of the group receiving momotamana were lower than those of the group receiving only the purified feed.
[0027]

In addition, as shown in Table 4, the amount of triglyceride and cholesterol accumulated in the liver of the group to which momotamana was fed was significantly lower than the group to which only the purified feed was fed.
[0028]

[0029]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, the substance which has an anti-obesity effect and an arteriosclerosis prevention / amelioration effect was able to be obtained from Momotamana as a raw material. Furthermore, it could be easily used as a material for medicines and foods and drinks.

Claims (8)

A pharmaceutical having an effect of preventing body fat accumulation or reducing body fat, comprising, as an active ingredient, an extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant of Momotamana. A food or drink having an effect of preventing body fat accumulation or reducing body fat, comprising, as an active ingredient, an extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant body of Momota mana. Pharmaceuticals that have an inhibitory effect on digestion and absorption of fat or a function of lowering triglyceride in blood as an active ingredient, using an extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant or a plant of Momotamana . An extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant or a plant of Momotamana as an active ingredient, and having a digestive absorption inhibitory effect of fat or a neutral fat lowering effect in blood. Goods. A pharmaceutical having an anticholesterol effect, comprising, as an active ingredient, an extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant body of Momotamana. A food or drink having an anticholesterol effect, comprising, as an active ingredient, an extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant of Momotamana. An antiobesity agent comprising, as an active ingredient, an extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant of Momotamana or a plant. An arteriosclerosis preventive agent comprising, as an active ingredient, an extract obtained by extracting water or an organic solvent alone or a mixture thereof from a plant of Momotamana or a plant.